Abstract
| Original language | English |
|---|---|
| Pages (from-to) | 122 - 131 |
| Number of pages | 10 |
| Journal | Journal of Steroid Biochemistry and Molecular Biology |
| Volume | 131 |
| Issue number | 3-5 |
| DOIs | |
| Publication status | Published - 2012 |
Cite this
}
Breaking through a roadblock in prostate cancer research: An update on human model systems. / Toivanen, Roxanne; Taylor, Renea A; Pook, David W; Ellem, Stuart J; Risbridger, Gail P.
In: Journal of Steroid Biochemistry and Molecular Biology, Vol. 131, No. 3-5, 2012, p. 122 - 131.Research output: Contribution to journal › Article › Research › peer-review
TY - JOUR
T1 - Breaking through a roadblock in prostate cancer research: An update on human model systems
AU - Toivanen, Roxanne
AU - Taylor, Renea A
AU - Pook, David W
AU - Ellem, Stuart J
AU - Risbridger, Gail P
PY - 2012
Y1 - 2012
N2 - Prostate cancer is a prevalent disease that affects the aging male population. Whilst there have been significant advances of our biological understanding of the disease, clinical translation of promising agents continues to lag behind. In part, this is due to a paucity of relevant experimental and pre-clinical models required to further develop effective prevention and therapeutic strategies. Genetically modified cell lines fail to entirely represent the genetic and molecular diversity of primary human specimens, particularly from localised disease. Furthermore, primary prostate cancer tissues are extremely difficult to grow in the laboratory and virtually all human models, whether they grow as xenografts in immune-deficient animals or as cell cultures, are genetically modified by the investigator or derived from patients with advanced metastatic disease. In this review, we discuss the latest advances and improvements to current methods of xenografting human primary prostate cancer, and their potential application to translational research. This article is part of a Special Issue entitled Steroids and cancer .
AB - Prostate cancer is a prevalent disease that affects the aging male population. Whilst there have been significant advances of our biological understanding of the disease, clinical translation of promising agents continues to lag behind. In part, this is due to a paucity of relevant experimental and pre-clinical models required to further develop effective prevention and therapeutic strategies. Genetically modified cell lines fail to entirely represent the genetic and molecular diversity of primary human specimens, particularly from localised disease. Furthermore, primary prostate cancer tissues are extremely difficult to grow in the laboratory and virtually all human models, whether they grow as xenografts in immune-deficient animals or as cell cultures, are genetically modified by the investigator or derived from patients with advanced metastatic disease. In this review, we discuss the latest advances and improvements to current methods of xenografting human primary prostate cancer, and their potential application to translational research. This article is part of a Special Issue entitled Steroids and cancer .
UR - http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=22342674
U2 - 10.1016/j.jsbmb.2012.01.005
DO - 10.1016/j.jsbmb.2012.01.005
M3 - Article
VL - 131
SP - 122
EP - 131
JO - Journal of Steroid Biochemistry and Molecular Biology
JF - Journal of Steroid Biochemistry and Molecular Biology
SN - 0960-0760
IS - 3-5
ER -